No recent analyst price targets found for LZAGF.
Latest News for LZAGF
Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside
H1 results showed 16% sales growth, a 44% net profit increase, and EBITDA margin expansion to 34.8%, driven by higher asset utilization and segment outperformance. Integrated Biologics, Advanced Synthesis, and Specialized Modalities each delivered double-digit growth. Management raised its 2026 CORE EBITDA margin outlook to 33–34% while maintaining 11–12% sales growth guidance. Our buy rating is confirmed.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LZAGF.
Senate Trading
No Senate trades found for LZAGF.
U.S. House Trading
No House trades found for LZAGF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.